Trends in teicoplanin loading dose implementation from 2010 to 2019 and evaluation of safety and efficacy factors: a retrospective cohort study based on a Japanese administrative claims database

Table 3 Clinical variables related to liver injury in the administration of teicoplanin

	Univariable			Multivariable
	OR	95% CI	p value	OR	95% CI	p value
Treatment details
Treatment duration (day)	0.98	0.95‒1.01	0.16	0.97	0.94‒1.00	0.078
Total dose for 3 days [≤ 1,600 mg vs. 1,600 <]	1.11	0.77‒1.60	0.58	0.99	0.63‒1.55	0.96
Reimbursement
Treatment and management fee for specific drugs	1.07	0.64‒1.77	0.80	1.11	0.59‒2.09	0.74
Drug management and guidance fee	1.36	0.79‒2.36	0.27	1.48	0.78‒2.82	0.24
Concomitant drug
Anti-infection drugs	0.52	0.28‒0.94	0.032	0.43	0.22‒0.82	0.011
Antipyretic analgesics and anti-inflammatory drugs	1.42	0.86‒2.35	0.17	1.61	0.90‒2.88	0.11
Anticancer drugs	1.33	0.30‒5.96	0.71	1.58	0.29‒8.69	0.60
Gastrointestinal drugs	1.06	0.55‒2.05	0.87	1.12	0.53‒2.37	0.77
Psychiatric or neurological drugs	0.75	0.43‒1.32	0.32	0.61	0.32‒1.14	0.12
Metabolic diseases drugs	1.15	0.68‒1.95	0.59	1.41	0.79‒2.52	0.24

CCI Charlson comorbidity index, OR odds ratio, 95% CI 95% confidence interval

ISSN: 2055-0294